UCBJY (UCBJY) Stock Price & Analysis
UCBJY (UCBJY) rose 1.02% to USD 151.74 as of June 9, 2026 at 23:57 UTC, according to Nexqual real-time market data.
UCBJY last closed at USD 150.21; the session ranged USD 150.6–152.79 on volume of 1,999 shares. Market capitalization is $57.81B, with a 52-week range of USD 89–168.76 (PNK). Source: Nexqual, June 9, 2026 at 23:57 UTC.
Key Statistics (as of June 9, 2026 at 23:57 UTC)
| Price | USD 151.74 |
|---|---|
| Change | ▲ 1.02% (up) |
| Previous Close | USD 150.21 |
| Open | USD 152.33 |
| Day Range | USD 150.6 – 152.79 |
| 52-Week Range | USD 89 – 168.76 |
| Volume | 1,999 shares |
| Market Cap | $57.81B |
| Exchange | PNK |
Technical Analysis (UCBJY)
Nexqual's technical model rates UCBJY "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 23:57 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.06 (neutral) |
| vs SMA50 | Above (USD 144.92) |
| MACD | 2.31 (positive) |
Analyst Ratings (UCBJY)
Wall Street analysts rate UCBJY "Strong Buy" based on 2 analysts, with a mean price target of USD 162.45 (range USD 160.69–164.2), per Nexqual as of June 9, 2026 at 23:57 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 162.45 |
| High Target | USD 164.2 |
| Low Target | USD 160.69 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (UCBJY)
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Financials & Fundamentals (UCBJY)
| Total Revenue | $7.74B |
|---|---|
| Revenue Growth (YoY) | +26.60% |
| Gross Margin | +74.29% |
| Operating Margin | +30.39% |
| Profit Margin | +20.13% |
| ROE | +14.91% |
| Debt / Equity | 20.66 |
| Current Ratio | 1.38 |
| Total Cash | $2.36B |
| Total Debt | $2.24B |
| Free Cash Flow | $1.83B |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Financial Health Score (UCBJY)
Nexqual rates UCBJY's overall financial health "Strong" across five dimensions, as of June 9, 2026 at 23:57 UTC.
| Growth | Strong — Revenue +26% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 74%, operating 30% |
| Balance Sheet | Strong — $2.36B cash vs $2.24B debt, net cash position |
| Cash Flow | Strong — FCF $1.83B, 24% margin |
| Efficiency | Mixed — ROE 15%, ROA 7.0% |
Ownership (UCBJY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 380.72M |
| Float | 239.72M |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Leadership (UCBJY)
UCBJY is led by Jean-Christophe Tellier (age 66), CEO & Executive Director, per Nexqual as of June 9, 2026 at 23:57 UTC.
| CEO & Executive Director | Jean-Christophe Tellier (age 66) |
|---|---|
| Executive VP & CFO | Sandrine Dufour (age 59) |
| Executive VP & Chief Scientific Officer | Alistair Henry (age 58) |
| Executive Vice President of Patient Evidence | Emmanuel Caeymaex (age 56) |
| Executive Vice President of Patient Supply | Kirsten Lund-Jurgensen (age 66) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MKKGY | Merck KGaA | USD 32 | ▲ 2.11% |
| SAUHY | Straumann Holding AG | USD 11.95 | ▲ 2.4% |
| CSLLY | CSL Ltd. | USD 17.44 | ▲ 1.87% |
| GNMSF | Genmab A/S | USD 249 | ▼ 0.18% |
| FSNUY | Fresenius SE & Co. KGaA | USD 10.82 | ▲ 0.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:57 UTC. This page is informational and not investment advice.